Literature DB >> 10279322

Adverse drug reaction program using pharmacist and nurse monitors.

L J Miwa, R J Randall.   

Abstract

The feasibility of instituting an adverse drug reaction (ADR) monitoring program was examined. Nurses and pharmacists were requested to fill out an ADR report form whenever a change in a patient's condition or a medication order raised suspicion of a possible ADR. The reports were investigated by the clinical pharmacy resident and evaluated for probable causal relationship, severity, and mechanism. The process used for reporting ADRs is described, and the parameters used to define an ADR are defined. The success of this program in increasing the number of ADR reports is evaluated, and the amount of time required by the various monitors is estimated. This voluntary ADR reporting system did increase ADR documentation in the study institution and may be adopted by P & T Committees in other hospitals.

Entities:  

Mesh:

Year:  1986        PMID: 10279322

Source DB:  PubMed          Journal:  Hosp Formul        ISSN: 0098-6909


  4 in total

1.  Academic detailing improves identification and reporting of adverse drug events.

Authors:  R G Schlienger; T F Lüscher; R A Schoenenberger; W E Haefeli
Journal:  Pharm World Sci       Date:  1999-06

2.  Development of a computerized adverse drug event monitor.

Authors:  R S Evans; S L Pestotnik; D C Classen; S B Bass; R L Menlove; R M Gardner; J P Burke
Journal:  Proc Annu Symp Comput Appl Med Care       Date:  1991

Review 3.  Strategies to improve adverse drug reaction reporting: a critical and systematic review.

Authors:  Cristian Gonzalez-Gonzalez; Elena Lopez-Gonzalez; Maria T Herdeiro; Adolfo Figueiras
Journal:  Drug Saf       Date:  2013-05       Impact factor: 5.606

4.  A comparison of active surveillance programs including a spontaneous reporting model for phamacovigilance of adverse drug events in a hospital.

Authors:  Il Seon Yun; Myung Jin Koo; Eun Hye Park; Sung-Eun Kim; Jae-Hyun Lee; Jung-Won Park; Chein-Soo Hong
Journal:  Korean J Intern Med       Date:  2012-11-27       Impact factor: 2.884

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.